prognostic indicators

Research in Review

Biomarker-Driven Treatment Does Not Improve NSCLC Outcomes

05/15/2017

JCP Editors

Selecting patients with cyclooxygenase-2 (COX-2) expression by immunohistochemistry fails to improve survival outcomes in non-small cell lung cancer (NSCLC), according to research published in the Journal of Clinical...

...

05/15/2017

Journal of Clinical Pathways

Research in Review

New Biomarker Helps Predict PFS in Patients With Type of NSCLC

05/05/2017

JCP Editors

Patients with ALK-rearranged non-small cell lung cancer (NSCLC) who are treated with crizotinib may experience increased progression-free survival (PFS) with a decrease in a type of circulating tumor cells, according...

...

05/05/2017

Journal of Clinical Pathways

Research in Review

Serum Marker Helps Predict Response to CAR-T Therapy in Lymphoma

04/28/2017

JCP Editors

Patients with relapsed or refractory lymphoma who achieve durable remission after low-dose conditioning chemotherapy and anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tend to have high serum levels of a...

...

04/28/2017

Journal of Clinical Pathways

Research in Review

New Prognostic Marker Identified for Diffuse Large B-Cell Lymphoma

04/27/2017

JCP Editors

A recent meta-analysis identified a strong correlation between an inflammation marker and survival outcomes for patients with diffuse large B-cell lymphoma, published in PLOS One (published online April 25, 2017;...

A...

04/27/2017

Journal of Clinical Pathways

Research in Review

Bone Model Examines Treatment Effectiveness for Breast Cancer Metastases

04/24/2017

JCP Editors

A bone metastasis model has been created that simulates interactions between metastatic breast cancer cells and bone cells to determine effectiveness of different treatments, published in Nature Communications...

A bone...

04/24/2017

Journal of Clinical Pathways

Research in Review

Autologous Stem Cell Transplantation Improves Outcomes for Patients With MCL

04/11/2017

JCP Editors

Patients with mantle cell lymphoma (MCL) benefit from prolonged event-free survival (EFS) and overall survival (OS) when treated with autologous stem cell transplantation (ASCT) and total body irradiation, according...

...

04/11/2017

Journal of Clinical Pathways

Research in Review

Incorporating EGFR, ALK Gene Alterations Data Improves Survival Prediction for Patients With NSCLC

11/21/2016

JCP Editors

Patients with non-small cell lung cancer (NSCLC) may see improved survival predictions as a result of a new prognostic tool that includes EGFR and ALK gene alterations data, according to an analysis published...

...

11/21/2016

Journal of Clinical Pathways

Research in Review

Review Examines Prognostic Value of Tumor-Infiltrating Lymphocytes in Early Breast Cancer

11/15/2016

JCP Editors

Tumor-infiltrating lymphocytes (TILs) have been described in various tumors, including breast cancer. In early breast cancer, the presence of TILs is associated with better outcomes and response to therapy. A review...

...

11/15/2016

Journal of Clinical Pathways

Research in Review

Health Insurance Status a Significant Influencer of Cancer Outcomes

08/08/2016

JCP Editors

Two studies published online in the journal Cancer have shown that patients’ health insurance status may impact outcomes following cancer diagnosis. Using population-based data from the Surveillance, Epidemiology,...

Two...

08/08/2016

Journal of Clinical Pathways

Research in Review

Lymph Node Ratio an Effective Indicator of Prognosis in Rectal Cancer

06/20/2016

JCP Editors

Lymph node ratio (LNR) may be a significant indicator of prognosis in patients with rectal cancer and could be used to better stratify patients in clinical trials, claims a recently published...

Lymph...

06/20/2016

Journal of Clinical Pathways